Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral phenotype and genotype as markers in clinical trials.

Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association - 1 Jan 1995

Katzenstein D A

Abstract excerpt

Treatment of AIDS and HIV infection is increasingly dependent on the use of surrogate markers to assess the efficacy of drug and biologic therapies in individual patients and in the clinical trials. Recent developments in laboratory techniques have resulted in new assays to measure circulating viral RNA in HIV-infected individuals, standardized methods to assess genotypic changes in virus associated with drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA, Viral
Share to Genotype
Share to HIV Infections

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenotype

Share to Biomarkers

Share to Disease Progression

Share to DNA, Viral

Share to Drug Resistance, Microbial

Source

Identifiers

PMID: 7552510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral phenotype and genotype as markers in clinical trials.PMID 7552510Read ↗

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.Semantic proximity Read ↗

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.Semantic proximity Read ↗

Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Quantification of HIV-1 RNA during antiretroviral therapy: association with viral phenotype and development of resistance.Semantic proximity Read ↗

Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.Semantic proximity Read ↗

Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.Semantic proximity Read ↗

Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.Semantic proximity Read ↗

Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children.Semantic proximity Read ↗

Individualization of therapy using viral markers.Semantic proximity Read ↗

HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.Semantic proximity Read ↗

The role of HIV type 1 phenotype and genotype in long-term responders to zidovudine therapy.Semantic proximity Read ↗

Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.